Addendum
Atezolizumab (NSCLC, adjuvant) - Addendum to Commission A22-67
Report documents
-
Addendum
Atezolizumab (NSCLC, adjuvant) - Addendum to Commission A22-67
Dossier assessment
Indication:
Adult patients with completely resected NSCLC at high risk of recurrence after platinum-based chemotherapy whose tumours express PD-L1 in ≥ 50% of the tumour cells and who do not have EGFR mutations or ALK-positive NSCLC; adjuvant treatment
Result of dossier assessment:
Unchanged after addendum: added benefit not proven
Additional information
Federal Joint Committee (G-BA)
2023-01-05 A G-BA decision was published.
Project details
- Project no.
- A22-124
- Commission
- Commission awarded on 22.11.2022 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
Connected Projects
-
Dossier assessment
Atezolizumab (NSCLC) – Benefit assessment according to § 35a SGB V
Status: Commission completed